Form 4 for KURA Kura Oncology, Inc.
Accepted 2026-08-24 17:30:03 ET · period of report 2026-08-24 · accession 0001193125-26-363812 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2026-08-24 17:30 | 2026-08-24 | KURA | WILSON TROY EDWARD | Pres, CEO, Dir | P - Purchase | $12.39 | +100.0K | 479.2K | +26% | +$1.24M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-08-24 | P | A | 100,000 | $12.39 | 479,194 | I by One Fish Two Fish Revocable Trust | — | — | (F1) This transaction was executed in multiple trades at prices ranging from $11.47 to $12.85. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |